Translational Capabilities: Seamless phase I to phase II transition (Milestone 4.Y)
Timeline Start - End2024 - 2025
Research Implementation AreaTranslational Tools, Infrastructure, and Capabilities
Evaluate and update current trial funding models to ensure the ability to test novel first-in-class therapeutics in the context of the full range of expenses and time frames required for robust evaluation and sharing.
- Create a research program that enables academic institutions and small biopharma companies developing first-in-class AD/ADRD therapeutics to conduct first in human trials and seamlessly transition to early-stage clinical trials in the intended patient population.
Summary of Key Accomplishments
This milestone has yet to be initiated. Accomplishments are forthcoming.
The key accomplishments summary is current as of July 2022.